Trial Profile
A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Plus Sorafenib in Women With Node Positive or High-Risk Early Stage Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Ductal carcinoma; Early breast cancer
- Focus Adverse reactions
- 02 May 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 02 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2008 Status changed from recruiting to in progress.